Cancer Therapies
Enzyme Ribonucleotide Reductase Inhibitor Trial Initiated
Published in Cancer Weekly, August 14th, 2001
The study is designed to determine the safety and maximum tolerated dose of cisplatin when administered with Triapine in patients with advanced cancer. The study is currently open at the Arizona Clinical Research Center in Tucson, Arizona. Triapine is a potent inhibitor of the enzyme ribonucleotide reductase. In preclinical studies, Triapine inhibits DNA synthesis, slows or stops cancer cell division, and disrupts repair of DNA damage caused by several standard anti-cancer agents including cisplatin.
...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
Source: Cancer Weekly (2001-08-14)
More Articles from Cancer Weekly
- Acute Lymphoblastic Leukemia
Malignant Stem Cells Can Lack CD38 Expression - Breast Cancer
More Vascular Density In Smaller Size Tumors But Not Linked To Outcome - Cancer Therapy
COX-2 Inhibition Reduces Murine Mammary Tumors Via Multiple Processes - Eye Cancer
Scientists Find Similar Survival Rates For Two Treatments - Glioblastoma Multiforme
Possible Mechanism Of Brain Tumor Progression Identified - Oncolytic Viruses
Crippled Herpesvirus Is Transformed Into A Better Cancer Killer - More from this issue of Cancer Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
